Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06967181) titled 'A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults' on May 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: CyanVac LLC

Condition: Mumps

Intervention: Biological: CVM150 Biological: CVM26

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: May 14, 2025

Target Sample Size: 60

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/ct2/show/NCT06967181...